Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | DDX3X | O00571 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.54 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8172216 | 0.99 | MEN1 (0.64) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL641425 | 0.87 | MEN1 (0.59) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL7529513 | 0.84 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL28467635 | 0.83 | MEN1 (0.51) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL3869188 | 0.83 | MEN1 (0.67) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL1797099 | 0.83 | MAPT (0.61) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL6192945 | 0.83 | MAPT (0.61) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL7560437 | 0.82 | SMN1; SMN2 (0.51) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL17560621 | 0.82 | MAPT (0.59) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL1258976 | 0.81 | MAPT (0.59) | MEN1KMT2ASMN1; SMN2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016035008-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016035008-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2016-03-10 | — | — | WO | disclosed |
| US-8404731-B2 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120196906-A1 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PTPase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-7723369-B2 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100113331-A1 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PtPase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-1991544-A2 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS | Transtech Pharma, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070191385-A1 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | VTV THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2007089857-A2 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191385-A1 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | PTP4A1, PTPRJ, PTP4A2 | MEN1 4542/4885KMT2A 2419/4885SMN1; SMN2 4462/4885 |
| US-20100113331-A1 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PtPase Inhibitors | PTP4A1, PTPRJ, PTP4A2 | MEN1 4542/4885KMT2A 2419/4885SMN1; SMN2 4462/4885 |
| US-20120196906-A1 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PTPase Inhibitors | PTP4A1, PTPRJ, PTP4A2 | MEN1 4542/4885KMT2A 2419/4885SMN1; SMN2 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.